hypertension
Conditions
Interventions
Intervention group:Participants will take 20 g of dried Lycium barbarum powder provided by the research team, dissolved in 200 mL of warm water and consumed orally at 14:00 every day, for 30 consecuti
Control group:Participants in the control group consumed a placebo beverage at the same schedule. The placebo was identical in appearance, taste, and preparation method to the intervention drink but c
Sponsors
Chengdu Center for Disease Control and Prevention
Eligibility
Sex/Gender
All
Age
65 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1.Age = 60 years, male or female. 2.Hypertension diagnosis: office blood pressure =140/90 mmHg measured on three separate visits without antihypertensive medication, or a history of hypertension with current use of antihypertensive medication even if blood pressure <140/90 mmHg. 3.No plans to relocate or travel during the intervention period, with ability to attend scheduled follow-up visits. 4.Renal function: estimated glomerular filtration rate (eGFR) =60 mL/min/1.73 m² and urinary albumin-to-creatinine ratio (UACR) 30–300 mg/g on recent laboratory tests. 5.Willing and able to comply with the intake of the provided Lycium barbarum residue powder during the study. 6.Participants, if conscious and capable, must provide written informed consent by themselves; if unable to do so due to illness or other reasons, consent must be obtained from a cohabiting family member or legally authorized representative.
Exclusion criteria
Exclusion criteria: 1.Patients with malignant tumors, acute myocardial infarction, stroke within the past three months, or other severe diseases, with an expected survival time of less than one year; 2.Patients with Cushing's syndrome or primary aldosteronism; 3.Patients with acute illnesses such as upper respiratory tract infection, fever, or severe diarrhea; 4.Patients with disabilities such as deafness or dementia, or with severe depression or other psychiatric disorders that prevent normal communication; 5.Patients who have undergone major gastrointestinal surgery within the past five years (including cholecystectomy, appendectomy, or partial resection of the small intestine); 6.Patients with irritable bowel syndrome (IBS), or constipation induced by tumors, inflammatory responses, metabolic diseases, or medications; 7.Patients with a history of peptic ulcer, gastrointestinal bleeding, polyps, masses, growth retardation, or malignancy; 8.Patients with mobility difficulties who cannot attend scheduled follow-ups, or who fail to complete follow-up visits after enrollment; 9.Patients who have used antibiotics, proton pump inhibitors, laxatives, antidiarrheal agents, probiotics, or prebiotics within the past month; 10.Pregnant or potentially pregnant women, and individuals otherwise deemed unsuitable for the intervention; 11.Patients whom the investigators consider inappropriate for inclusion. Note: Any patient who meets any of the above criteria will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum TMAO level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary TMAO level;Serum FMO3 level;Gut microbiota alpha diversity (ACE, Chao1, Shannon, Simpson, PD_whole_tree);Gut microbiota beta diversity;Differential abundance analysis (LEfSe);Functional pathway prediction (PICRUSt2); IL-6 level;TNF-a level;Serum IL-18 level;KIM-1 level;NGAL level;NF-?B level;PERK level;CaMKII level;ANGII level;Alanine aminotransferase (ALT);Aspartate aminotransferase (AST);Total bilirubin (TBIL);Urea (UREA);Creatinine (CREA);Estimated glomerular filtration rate (eGFR);Uric acid (UA);Short-chain fatty acids (SCFAs) metabolomics; | — |
Countries
China
Contacts
Public ContactMin Feng
Chengdu Center for Disease Control and Prevention
Outcome results
None listed